Semaglutide Efficacy Varies Across Ancestries and Is Modulated by Genetic Variation in PTPRU
Haas R, Margolis MP, Wei A, Yamaguchi TN, et al.
Summary
Analysis of 93,936 participants from the UCLA ATLAS Community Health Initiative revealed that semaglutide efficacy varies across ancestry groups and is associated with polygenic scores for type 2 diabetes. The study identified that genetic variation in PTPRU modulates semaglutide response, providing the first pharmacogenomic insights into GLP-1 RA efficacy across diverse populations.
Clinical Significance
Published in Cell — one of the highest-impact scientific journals — this study provides the first large-scale evidence that semaglutide response is ancestry-dependent and genetically modulated. This has profound implications for precision medicine approaches to GLP-1 RA prescribing.
Key Findings
- Study size: 93,936 participants across 5 continental and 36 fine-scale ancestry groups
- Key discovery: Semaglutide efficacy varies by ancestry
- Pharmacogenomics: PTPRU genetic variation modulates semaglutide response
- Polygenic scores: T2D PGS associated with semaglutide effectiveness
- Journal impact: Published in Cell — top-tier basic science journal
Clinical Implications
This is a landmark study for precision medicine in obesity and diabetes treatment. The finding that PTPRU variants modulate semaglutide response suggests that genetic testing could eventually guide GLP-1 RA selection and dosing. The ancestry-dependent efficacy differences also highlight the importance of diverse representation in clinical trials.
Sorodne raziskave
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach
This Novo Nordisk study used model-informed drug development to evaluate whether semaglutide 1.7 mg …
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…